Cocrystal Pharma, Inc. Board of Directors

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Mr. James J. Martin CPA, M.B.A.

Mr. James J. Martin CPA, M.B.A.

Co-CEO, CFO & Corporate Secretary

Dr. Sam Lee Ph.D.

Dr. Sam Lee Ph.D.

Co-Founder, Co-CEO & President

Dr. Roger D. Kornberg Ph.D.

Dr. Roger D. Kornberg Ph.D.

Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.